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Hemoglobin As A Predictor For COVID-19 Disease Severity
Abstract
Background
Background: The dilemma of who is at highest risk for COVID-19 severe disease and death persists.
Hemoglobin levels may be an indicator of COVID-19 disease severity. There is inconsistent data on
Emergency Department (ED) hemoglobin levels and severity of disease. Our objective was to examine if
COVID-19 patients presenting with abnormal hemoglobin levels have an increased risk of severe disease
and in-hospital mortality.
Methods
Methods: We conducted a retrospective cohort study at Berkshire Medical Center in Pittsfield, MA to
investigate the relationship of COVID-19 disease severity with hemoglobin level. Inclusion criteria
consisted of ED patients over 18 years with a COVID-19 diagnosis from July 1, 2021, to November 1,
2021. Exclusion criteria consisted of duplicate visits and patients without a hemoglobin value recorded.
Patients with anemia were stratified by severity. Disposition categories from most to least severe were:
ICU/PCU, medical floor, or discharge from ED. In-hospital mortality was recorded. Backward linear
regression followed by z-tests were used for each abnormal hemoglobin category versus normal
hemoglobin category.
Results
Results: The four-month period included 341 ED visits coded for COVID-19. After excluding 113 visits, 228
were eligible for analysis. There were 132 discharged from the ED, 64 admitted to the medical floor, 32 to
ICU/PCU, and 19 deaths. Backwards linear regression showed hemoglobin category was a significant
predictor of hospital disposition (p < 0.0001) and mortality (p = 0.07). Z-test showed a significant
difference in disposition for normal hemoglobin versus mild anemia (z = 2.1927, p = 0.03) and normal
hemoglobin versus moderate/severe anemia (z = 3.6225, p = 0 0003). Z-test showed a significant
difference in death for normal hemoglobin versus moderate/severe anemia (z = 3.2949, p = 0.001).
Normal hemoglobin versus elevated hemoglobin had no significant difference for disposition (z = 0.356, p
= 0.72) or death (z = 1.786, p = 0.07).
Discussion
Discussion: Abnormal hemoglobin is associated with severity of disease and death COVID-19 patients.
Increasingly severe anemia is more associated with severity of disease and death. Elevated hemoglobin
is not associated with severity of disease or death.
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Hemoglobin as a Predictor for COVID-19
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Nicholas Sarcia a,*, Dan Thai a, Andrea M. Bodine b
a
b
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Abstract
Background: The dilemma of who is at highest risk for COVID-19 severe disease and death persists. Hemoglobin levels
may be an indicator of COVID-19 disease severity. There is inconsistent data on Emergency Department (ED) hemoglobin levels and severity of disease. Our objective was to examine if COVID-19 patients presenting with abnormal
hemoglobin levels have an increased risk of severe disease and in-hospital mortality.
Methods: We conducted a retrospective cohort study at Berkshire Medical Center in Pittsﬁeld, MA to investigate the
relationship of COVID-19 disease severity with hemoglobin level. Inclusion criteria consisted of ED patients over 18 years
with a COVID-19 diagnosis from July 1, 2021, to November 1, 2021. Exclusion criteria consisted of duplicate visits and patients without a hemoglobin value recorded. Patients with anemia were stratiﬁed by severity. Disposition categories from
most to least severe were: ICU/PCU, medical ﬂoor, or discharge from ED. In-hospital mortality was recorded. Backward
linear regression followed by z-tests were used for each abnormal hemoglobin category versus normal hemoglobin category.
Results: The four-month period included 341 ED visits coded for COVID-19. After excluding 113 visits, 228 were
eligible for analysis. There were 132 discharged from the ED, 64 admitted to the medical ﬂoor, 32 to ICU/PCU, and 19
deaths. Backwards linear regression showed hemoglobin category was a signiﬁcant predictor of hospital disposition
(p < 0.0001) and mortality (p ¼ 0.07). Z-test showed a signiﬁcant difference in disposition for normal hemoglobin versus
mild anemia (z ¼ 2.1927, p ¼ 0.03) and normal hemoglobin versus moderate/severe anemia (z ¼ 3.6225, p ¼ 0 0003). Ztest showed a signiﬁcant difference in death for normal hemoglobin versus moderate/severe anemia (z ¼ 3.2949,
p ¼ 0.001). Normal hemoglobin versus elevated hemoglobin had no signiﬁcant difference for disposition (z ¼ 0.356,
p ¼ 0.72) or death (z ¼ 1.786, p ¼ 0.07).
Discussion: Abnormal hemoglobin is associated with severity of disease and death COVID-19 patients. Increasingly
severe anemia is more associated with severity of disease and death. Elevated hemoglobin is not associated with severity
of disease or death.
Keywords: COVID-19, Hemoglobin, Anemia, Delta variant

1. Introduction

T

he dilemma of who is at highest risk for
COVID-19 severe disease and death persists.
In July 2021, the Delta variant became the dominant
strain in the United States causing more severe
disease and vaccine breakthrough. Through
October 2021, there had been over 233 million cases
and 4.8 million deaths worldwide.1 Multiple comorbid conditions and risk factors have been linked

to more severe disease such as increased age, hypertension, cardiovascular disease, diabetes,
obesity, and chronic lung disease.2,3 Worse outcomes have been associated with abnormal laboratory values of liver enzymes, kidney function, and
inﬂammatory markers.4 COVID-19 association with
comorbidities and laboratory values may present in
a similar fashion to other acute and chronic respiratory conditions. Patients with severe acute respiratory diseases, such as community-acquired
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pneumonia have an increased risk of mortality if
anemia is present.5 Hemoglobin levels may be an
indicator or precursor of COVID-19 disease severity.
There is inconsistent data on hemoglobin levels in
Emergency Department (ED) visits and severity of
disease in COVID-19 patients. Some studies have
shown an association of severity of anemia and
worse outcomes in the hospital,6,7 while others have
shown no signiﬁcant difference.8,9 One study
observed an increase in mortality with elevated
hemoglobin levels.10 Worse outcomes have been
deﬁned as ICU admission rate and mortality,
although data has shown that these two parameters
do not always accompany each other.6,7 Hemoglobin is commonly measured in the ED during hospital visits. If altered hemoglobin on initial blood
work is predictive of more severe disease, it could
be used as an early risk stratiﬁcation tool for patients who ﬁrst arrive at the ED. This could also be
used to classify patients who have a known anemia
to be at higher risk.
The purpose of this study was to investigate hemoglobin levels on initial blood work and determine
whether it could be used as a tool to predict outcomes for COVID-19 patients. Our objective was to
examine if COVID-19 patients presenting with
abnormal hemoglobin levels have an increased risk
of severe disease and in-hospital mortality. We hypothesized that COVID-19 patients who present
with an abnormal hemoglobin would have more
severe disease and a higher in-hospital mortality
rate than COVID-19 patients with normal
hemoglobin.

2. Methods
We conducted a retrospective cohort study at
Berkshire Medical Center (BMC) in Pittsﬁeld, MA to
investigate the relationship of COVID-19 disease
severity and in-hospital mortality with hemoglobin
(Hgb) levels. IRB exemption was obtained.
Inclusion criteria consisted of patients 18 years
and older presenting to the ED with a diagnosis of
COVID-19 from July 1, 2021, to November 1, 2021.
Records were reviewed for demographics of age,
sex, race, and vaccination status which was positive
if documented on ED record. Exclusion criteria
consisted of duplicate visits and patients who did

not have a recorded hemoglobin value. Duplicate
visits greater than or equal to 48 days were considered a new infection and counted as an additional
subject. Visits less than 48 days were subjected to
selection of the most severe presentation requiring
the highest level of care and exclusion of the other
visit(s) in the following order: in-hospital death,
highest level of care, lowest abnormal hemoglobin
value, highest abnormal hemoglobin value, all other
things being equal, choose the earliest visit.
Anemia was classiﬁed according to the World
Health Organization (WHO) deﬁnition (Table 1), as
hemoglobin (Hb) levels <13.0 g/dL in males and
<12.0 g/dL in females. Severity of anemia was
deﬁned in males by: mild 11e12.9 g/dL, moderate
8e10.9 g/dL, and severe <8 g/dL. Severity of anemia
was deﬁned in females by: mild 11e11.9 g/dL,
moderate 8e10.9 g/dL, severe <8 g/dL.11 Elevated
hemoglobin in males and females was deﬁned as
16 g/dL. These categories comprised the abnormal
hemoglobin groups. Severity of disease was
measured by hospital disposition with the most severe to mild as ICU/PCU (intensive care unit/progressive care unit), medical ﬂoor, or ED discharge.
In-hospital mortality was deﬁned as patients who
died before discharge. ICU admission was made
based upon the clinical judgment of the ICU
attending physician and ED provider. Patients who
required intubation and ventilation or had refractory hypoxia were generally admitted to the
ICU. When no beds were available in the ICU, patients were admitted to the PCU, which is an intermediate level of care between the medical ﬂoor
and ICU at BMC.
Data was obtained from BMC Medical Records
Department using ICD-10 codes for COVID-19 and
patients who presented initially through the ED.
Electronic medical records were reviewed for hemoglobin on initial CBC, in-hospital mortality, and
disposition to ICU/PCU, medical ﬂoor, or ED
discharge. Demographics of age at initial presentation, sex, race, and vaccination status were also
recorded independently. Patients with anemia were
then stratiﬁed by severity. Backward linear regression was used for analysis followed by z-tests to
compare each abnormal hemoglobin category to the
normal hemoglobin category. All data was deidentiﬁed.

Table 1. Hemoglobin categories.
Male
Female

Severe

Moderate

Mild

Normal

Elevated

<8 g/dL
<8 g/dL

8e10.9 g/dL
8e10.9 g/dL

11e12.9 g/dL
11e11.9 g/dL

13e15.9 g/dL
12e15.9 g/dL

16 g/dL
16 g/dL
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3. Results

58% moderate, 29% severe, and 50% elevated. Of
the subjects 53% were vaccinated. Vaccination status for each hemoglobin category consisted of 48%
normal Hgb, 71% mild, 75% moderate, 50% severe,
and 39% elevated (Table 2).
Hemoglobin levels ranged from 7.9 to 18.6. There
were a total of 154 normal Hgb, 36 mild, 17 moderate, 2 severe, and 19 elevated (Table 3). Distribution of each hemoglobin category for disposition ()
and death () are shown. Due to the small number of
subjects in the severe anemia group, the moderate
and severe categories were combined for analysis.
Five variables were used in backwards linear
regression to predict disposition: Age, Vaccination
status, Sex, Race, and Hemoglobin category. Of
these ﬁve variables, two remained signiﬁcant at the
alpha ¼ 0.10 level: Hemoglobin category (p < 0.0001)
and Age (p ¼ 0.002). Z-test compared normal

During the four-month period there were 341 ED
visits coded for COVID-19 in patients 18 and older.
After excluding 70 subjects who did not have a hemoglobin value and 45 repeat visits with two subjects in both exclusion criteria, there were a total of
228 subjects for analysis. One patient had a repeat
visit greater than 48 days which was counted as a
separate visit. There were a total of 132 discharged
from the ED, 64 admitted to the medical ﬂoor, and
32 to the ICU/PCU. Of the 228 subjects, 19 died
during their hospital stay (Fig. 1).
Ages ranged from 18 to 97 with an average age of
56. Average age in normal Hgb was 53, mild 62,
moderate 73, severe 78, and elevated 54. Males were
46% of the subjects. Males for each hemoglobin
category consisted of 64% normal Hgb, 39% mild,

Fig. 1. Study population.

Table 2. Demographics for hemoglobin categories.
Age (mean)
Males (%)
Race (white %)
Vaccinated (%)

Published by RocScholar, 2022

Normal

Mild

Moderate

Severe

Elevated

Total

53
64
91
48

62
39
92
71

73
58
94
75

78
29
100
50

54
50
89
39

56
46
91
53
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Table 3. Hgb Category for disposition and death.
Discharge
Floor
ICU/PCU
Death

Normal

Mild

Moderate

Severe

Elevated

99
42
13
8

16
13
7
3

4
4
9
5

0
2
0
0

13
3
3
3

Number of patients in each disposition and deaths.

hemoglobin versus mild anemia, moderate/severe
anemia, and elevated hemoglobin for disposition
with a signiﬁcance level of p  0.05. There was
signiﬁcant difference in disposition for normal hemoglobin versus mild anemia (z ¼ 2.1927, p ¼ 0.03)
and normal hemoglobin versus moderate/severe
anemia (z ¼ 3.6225, p ¼ 0 0003). There was no signiﬁcant difference in disposition for normal hemoglobin versus elevated hemoglobin (z ¼ 0.356,
p ¼ 0.72).
Five variables were used in backwards linear
regression to predict death: Age, Vaccination status,
Sex, Race, and Hemoglobin category. Of these ﬁve
variables, three remained signiﬁcant at the
alpha ¼ 0.10 level: Patient Age (p < 0.0001), Vaccination status (p ¼ 0.022), and Hemoglobin category
(p ¼ 0.07). Z-test compared normal hemoglobin
versus mild anemia. Moderate/severe anemia, and
elevated hemoglobin for death with signiﬁcance
level at p  0.05. There was a signiﬁcant difference
in death for normal hemoglobin versus moderate/
severe anemia (z ¼ 3.2949, p ¼ 0.001). There was no
signiﬁcant difference in death for normal hemoglobin versus mild anemia (z-score ¼ 0.7259, p ¼ 0.47)
or normal hemoglobin versus elevated hemoglobin
(z ¼ 1.786, p ¼ 0.07).

4. Discussion
We found COVID-19 patients who presented to
the ED with an abnormal hemoglobin had a significant association with severity of disease measured
by disposition, and death by in-hospital mortality.
For disposition, there was increasing signiﬁcance
with severity of anemia, particularly at the moderate-severe levels and no signiﬁcance with elevated
hemoglobin. For death, there was signiﬁcance with
moderate/severe anemia and no signiﬁcance with
mild anemia or elevated hemoglobin. We satisﬁed
our hypothesis that COVID-19 patients with
abnormal hemoglobin had more severe disease only
with the anemic groups and for in-hospital mortality
only with moderate/severe anemia. We were unable
to satisfy our hypothesis for severity of disease in the
elevated hemoglobin group and in-hospital mortality in mild anemia and elevated hemoglobin groups.

https://scholar.rochesterregional.org/advances/vol2/iss2/3
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Our ﬁndings of abnormal hemoglobin predicting
more severe disease and death are partially
consistent with other studies that have shown a
signiﬁcant association in either severity of disease
or death, but not both.6,7 Our data is inconsistent
with other studies that have shown no association
of anemia and severe illness or death,8,9 and an
association of death with elevated hemoglobin
which we found to be non-signiﬁcant.10 These inconsistencies may be related to our limitations
which include a lack of subject racial diversity
thereby decreasing the generalizability of the study,
and a small sample size, especially in the severe
anemia category which was combined with moderate anemia for analysis. We were unable to
determine if patients who were discharged to
another facility or home later died from disease. It
may be useful to record death out of the hospital
within a certain time frame. This study also has
several confounding variables such as chronic diseases or other abnormal laboratory values that may
have placed certain patients at higher risk. Patients
with chronic disease may have had a chronic
abnormal hemoglobin or have multiple diseases
that would subject them to placement at a higher
level of care such as the ICU/PCU or death. These
confounding factors can only be controlled for by a
more extensive study design and analysis. The
disposition of the patient is also dependent on the
provider which adds subjectivity to the analysis of
severity of disease.
Future studies that have a larger and diverse
sample size controlling for confounding variables
would be able to give a more precise interpretation
on severity of disease and death. Follow-up of patients after discharge may provide a better representation of the actual mortality rate. It also may be
useful to analyze data from different time periods to
compare with the delta variant, which was the
dominant source of infection in this study, versus
other strains.
The strengths of our study include addition of the
elevated hemoglobin category which fewer studies
have assessed, and the study population which was
concentrated during the delta variant outbreak. The
data from our study provides clinical relevance as it
suggests patients with abnormal hemoglobin to be
at higher risk for severe disease and death which
can be considered in assessing risk for COVID-19
disease in the ED. We can also emphasize the
importance of vaccination and additionally the risk
of death in the older population as it was a more
signiﬁcant predictor of death than the hemoglobin
category in our analysis.
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5. Conclusion
Within the limitations of the study, abnormal hemoglobin appears to be associated with severity of
disease and death COVID-19 patients. Increasingly
severe anemia is more associated with severity of
disease and death. Elevated hemoglobin is not
associated with severity of disease or death.
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